Viewing Study NCT06277167



Ignite Creation Date: 2024-05-06 @ 8:09 PM
Last Modification Date: 2024-10-26 @ 3:21 PM
Study NCT ID: NCT06277167
Status: COMPLETED
Last Update Posted: 2024-05-01
First Post: 2024-02-02

Brief Title: A Phase I Study in Healthy Participants
Sponsor: Kexing Biopharm Co Ltd
Organization: Kexing Biopharm Co Ltd

Study Overview

Official Title: A Randomized Double-Blind Placebo-Controlled Phase-I Clinical Study to Evaluate the Tolerability Safety and PK Profiles of Human Interferon Alfa 1b Inhalation Solution in Healthy Adult Subjects After Administration of Single Ascending Doses and Multiple Ascending Doses
Status: COMPLETED
Status Verified Date: 2024-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: A Randomized Double-Blind Placebo-Controlled Phase-I Clinical Study to Evaluate the Tolerability Safety and PK Profiles of Human interferon alfa 1b inhalation solution in Healthy Adult Subjects after Administration of Single Ascending Doses and Multiple Ascending Doses
Detailed Description: Primary objectiveTo evaluate the tolerability and safety of single and multiple aerosol inhalation of Human interferon alfa 1b inhalation solution in healthy adult subjects

Secondary objectives To evaluate the pharmacokinetic PK profiles of single and multiple aerosol inhalation of Human interferon alfa 1b inhalation solution in healthy adult subjects and to evaluate the immunogenicity of single and multiple aerosol inhalation of Human interferon alfa 1b inhalation solution in healthy adult subjects

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None